EXTON, Pa., March 29, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a collaboration and license agreement with Biocare Medical, LLC. Under the agreement, the parties will collaborate to develop and commercialize an immunohistochemical (IHC) diagnostic kit utilizing Morphotek's proprietary monoclonal antibody to specifically detect human folate receptor alpha (FRA) with Biocare's intelliPATH™ Automated Stainer. The agreement provides Biocare with a worldwide non-exclusive license to develop, manufacture and commercialize an IHC kit for detection of FRA on formalin-fixed paraffin-embedded (FFPE) tumor tissues.
FRA is a cell surface protein that is over-expressed in a variety of cancers including non-small cell lung adenocarcinoma and ovarian carcinoma. Studies have found its expression variable among different cancer types. In light of this variability, a diagnostic assay that can identify patients with FRA-positive cancers may enable better diagnosis and treatment of patients affected with FRA-expressing cancers. FRA is the target of Morphotek's lead therapeutic candidate, farletuzumab, which is currently being tested in several clinical trials against different types of cancers.
"We are excited to continue development of our first diagnostic product using a novel Morphotek antibody in cooperation with Biocare and their innovative IHC platform technology," stated Daniel J. O'Shannessy, Ph.D., Director of Diagnostic Development at Morphotek. "We believe that the development of a validated IHC assay (and subsequent submission to the FDA) will be a significant step forward for our drug development programs. Furthermore, it supports our human health care (hhc) mission by better defining a patient's disease subtype to help design more appropriate therapeutic regimens."
"Biocare is enthusiastic about joining with a leader in the app
|SOURCE Morphotek, Inc.|
Copyright©2010 PR Newswire.
All rights reserved